Citations

Clear

3942 citation(s) found for "To, Van".

Surgery for Cushing’s Syndrome: An Historical Review and Recent Ten‐year Experience
Porterfield, John R. , Thompson, Geoffrey B. , Chow, John T., Fryrear, Raymond, Heerden, Jon A. van, Farley, David R. , Atkinson, John L. D., Meyer, Fredric B. , Abboud, Charles F., Nippoldt, Todd B., Natt, Neena, Erickson, Dana , Carpenter, Paul C., Richards, Melanie L. , Carney, J. Aidan, Larson, Dirk, Schleck, Cathy D. , Churchward, Marilyn, Grant, Clive S., Young, William F. , Vella, Adrian

Mayo Clinic

World Journal of Surgery | January 14, 2008 | Volume: 32 | Issue: 5 | Pages: 659-677

10.1007/s00268-007-9387-6 | PMID 18196319 Get It

AbstractBackgroundCushing’s syndrome (CS), due to multiple etiologies, is a disorder associated with the ravages of cortisol excess. The purpose of this review article is to provide a historical synopsis of surgery for CS, review a recent 10‐year period of operative management at a tertiary care facility, and to outline a practical approach to diagnosis and management.Materials and MethodsFrom 1996 to 2005, 298 patients underwent 322 operative procedures for CS at Mayo Clinic, Rochester, Minnesota. A retrospective chart review was carried out. Data was gathered regarding demographics, preoperative assessment, procedures performed, and outcomes. Data are presented as counts and percentages. Five‐year survival rates were calculated where applicable by the Kaplan‐Meier method. Statistical analysis was carried out with SAS, version 9 (SAS Institute, Inc., Cary, NC).ResultsTwo‐hundred thirty‐one patients (78%) had ACTH‐dependent CS and 67 patients (22%) had ACTH‐independent CS. One‐hundred ninety‐six patients (66%) had pituitary‐dependent CS and 35 patients (12%) had ectopic ACTH syndrome. Fifty‐four patients (18%) had cortisol‐secreting adenomas, 10 patients (3%) had cortisol‐producing adrenocortical carcinomas, and 1% had other causes. Cure rates for first time pituitary operations (transsphenoidal, sublabial, and endonasal) were 80% and 55% for reoperations. Most benign adrenal processes could be managed laparoscopically. Five‐year survival rates (all causes) were 90%, 51%, and 23% for adrenocortical adenomas, ectopic ACTH syndrome, and adrenocortical carcinomas, respectively.ConclusionsSurgery for CS is highly successful for pituitary‐dependent CS and most ACTH‐independent adrenal causes. Bilateral total adrenalectomy can also provide effective palliation from the ravages of hypercortisolism in patients with ectopic ACTH syndrome and for those who have failed transsphenoidal surgery. Unfortunately, to date, adrenocortical carcinomas are rarely cured. Future successes with this disease will likely depend on a better understanding of tumor biology, more effective adjuvant therapies and earlier detection. Clearly, IPSS, advances in cross‐sectional imaging, along with developments in transsphenoidal and laparoscopic surgery, have had the greatest impact on today’s management of the complex patient with CS.
Quality Assessment for CT Colonography: Validation of Automated Measurement of Colonic Distention and Residual Fluid
Deshpande, Keshav K., Summers, Ronald M. , Uitert, Robert L. Van, Franaszek, Marek , Dwyer, Andrew J., Choi, J. Richard , Pickhardt, Perry J. , Brown, Línda Morris , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | November 20, 2007 | Volume: 189 | Issue: 6 | Pages: 1457-1463

10.2214/ajr.07.2327 | PMID 18029885 Get It

Molecular and Functional Characterization of Novel Glycerol-3-Phosphate Dehydrogenase 1–Like Gene ( GPD1-L ) Mutations in Sudden Infant Death Syndrome
Norstrand, David W. Van, Valdivia, Carmen R. , Tester, David J. , Ueda, Kazuo , London, Barry , Makielski, Jonathan C., Ackerman, Michael J. , London, Barry

Mayo Clinic

Circulation | October 29, 2007 | Volume: 116 | Issue: 20 | Pages: 2253-2259

10.1161/circulationaha.107.704627 | PMID 17967976 Get It

Background— Autopsy-negative sudden unexplained death, including sudden infant death syndrome, can be caused by cardiac channelopathies such as Brugada syndrome (BrS). Type 1 BrS, caused by mutations in the SCN5A -encoded sodium channel, accounts for ≈20% of BrS. Recently, a novel mutation in the glycerol-3-phosphate dehydrogenase 1–like gene ( GPD1-L ) disrupted trafficking of SCN5A in a multigenerational family with BrS. We hypothesized that mutations in GPD1-L may be responsible for some cases of sudden unexplained death/sudden infant death syndrome. Methods and Results— Using denaturing high-performance liquid chromatography and direct DNA sequencing, we performed comprehensive open-reading frame/splice site mutational analysis of GPD1-L on genomic DNA extracted from necropsy tissue of 83 unrelated cases of sudden unexplained death (26 females, 57 males; average age, 14.6±10.7 years; range, 1 month to 48 years). A putative, sudden unexplained death–associated GPD1-L missense mutation, E83K, was discovered in a 3-month-old white boy. Further mutational analysis was then performed on genomic DNA derived from a population-based cohort of 221 anonymous cases of sudden infant death syndrome (84 females, 137 males; average age, 3±2 months; range, 3 days to 12 months), revealing 2 additional mutations, I124V and R273C, in a 5-week-old white girl and a 1-month-old white boy, respectively. All mutations occurred in highly conserved residues and were absent in 600 reference alleles. Compared with wild-type GPD1-L, GPD1-L mutations coexpressed with SCN5A in heterologous HEK cells produced a significantly reduced sodium current ( P <0.01). Adenovirus-mediated gene transfer of the E83K–GPD1-L mutation into neonatal mouse myocytes markedly attenuated the sodium current ( P <0.01). These decreases in current density are consistent with sodium channel loss-of-function diseases like BrS. Conclusions— The present study is the first to report mutations in GPD1-L as a pathogenic cause for a small subset of sudden infant death syndrome via a secondary loss-of-function mechanism whereby perturbations in GPD1-L precipitate a marked decrease in the peak sodium current and a potentially lethal BrS-like proarrhythmic substrate.
Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis
Jeganathan, Karthik B. , Malureanu, Liviu, Baker, Darren J. , Abraham, Susan C. , Deursen, Jan M. van , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

The Journal of Cell Biology | October 16, 2007 | Volume: 179 | Issue: 2 | Pages: 255-267

10.1083/jcb.200706015 | PMID 17938250 Get It

The physiological role of the mitotic checkpoint protein Bub1 is unknown. To study this role, we generated a series of mutant mice with a gradient of reduced Bub1 expression using wild-type, hypomorphic, and knockout alleles. Bub1 hypomorphic mice are viable, fertile, and overtly normal despite weakened mitotic checkpoint activity and high percentages of aneuploid cells. Bub1 haploinsufficient mice, which have a milder reduction in Bub1 protein than Bub1 hypomorphic mice, also exhibit reduced checkpoint activity and increased aneuploidy, but to a lesser extent. Although cells from Bub1 hypomorphic and haploinsufficient mice have similar rates of chromosome missegregation, cell death after an aberrant separation decreases dramatically with declining Bub1 levels. Importantly, Bub1 hypomorphic mice are highly susceptible to spontaneous tumors, whereas Bub1 haploinsufficient mice are not. These findings demonstrate that loss of Bub1 below a critical threshold drives spontaneous tumorigenesis and suggest that in addition to ensuring proper chromosome segregation, Bub1 is important for mediating cell death when chromosomes missegregate.
Differential Characteristics of Neural Circulatory Control
Borne, Philippe van de , Neubauer‐Geryk, Jolanta , Rahnama, Mohsen, Jansens, Jean-Luc, Degaute, Jean Paul, Montano, Nicola , Porta, Alberto , Somers, Virend K. , Degaute, Jean-Paul

Mayo Clinic

Circulation | September 28, 2007 | Volume: 104 | Issue: 15 | Pages: 1809-1813

10.1161/hc4101.097248 | PMID 11591619 Get It

Background Reappearance of low-frequency (LF) (±0.10 Hz) oscillations in RR interval (RR) after cardiac transplantation is indicative of sympathetic efferent reinnervation. We hypothesized that restored LF oscillations in RR in heart transplant recipients (HTRs) are linked to oscillations in muscle sympathetic nerve traffic (MSNA). Methods and Results RR, RR variability, and MSNA were recorded 5±2 months (n=7, short-term HTRs) and 138±8 months (n=7, long-term HTRs) after heart transplantation and compared with matched hypertensive patients (n=7). A coherence function determined the coupling between LF oscillations in MSNA and RR. RR variance did not differ between short-term and long-term HTRs. However, LF variability was only 1±0.5 ms 2 in the short-term HTRs but was 15±8 ms 2 in the long-term HTRs ( P <0.05). Normalized LF variability was also higher in the long-term HTRs (40±14 normalized unites) versus the short-term HTRs (6±3 normalized united, P <0.05) but did not differ from the LF variability of the hypertensive patients. Long-term HTRs were taking less cyclosporine ( P <0.01) but had higher MSNA than the short-term HTRs (62±7 versus 31±7 burst/min, respectively, P <0.05). Coherence between LF oscillations in MSNA and RR was similar in the long-term HTRs (0.59±0.11) and the hypertensive patients (0.60±0.07) and was 3-fold greater than in the short-term HTRs (0.20±0.06, P <0.05). Conclusions Cardiac reinnervation after long-term heart transplantation is characterized by a restoration of the coherence between LF oscillations in RR and MSNA. Higher MSNA in long-term than in short-term HTRs suggests that time elapsed after cardiac transplantation may be a major determinant of sympathetic excitation in heart transplant recipients.
Independent Association Between Plasma Leptin Levels and Heart Rate in Heart Transplant Recipients
Winnicki, Mikołaj, Phillips, Bradley G., Accurso, Valentina, Borne, Philippe van de , Shamsuzzaman, Abu, Patil, Kirti T., Narkiewicz, Krzysztof , Somers, Virend K.

Mayo Clinic

Circulation | September 28, 2007 | Volume: 104 | Issue: 4 | Pages: 384-386

10.1161/hc2901.094150 | PMID 11468197 Get It

Background Leptin, the protein product of the ob gene, has been linked to a faster heart rate in animal and human studies. The interaction between leptin and heart rate in the denervated heart is not known. Therefore, we studied the relationship between plasma leptin levels and heart rate in heart transplant recipients. Methods and Results We studied 32 male patients (mean age, 56.5±9.3 years; range, 41 to 74 years) after orthotopic heart transplantation. All subjects underwent a physical examination, anthropometric measurements, blood chemistry analysis, and office blood pressure measurements. A blood sample was collected from each subject while fasting. In univariate analysis, heart rate was related to leptin levels ( r =0.47, P =0.007) but heart rate was not related to systolic or diastolic blood pressure, mean arterial pressure, body mass index, or catecholamines. Leptin levels were only strongly associated with heart rate and body mass index ( r =0.73, P <0.0001). In multivariate analysis, heart rate was independently and positively associated with leptin levels (F=2.61, P =0.017). We also observed a strong, independent association between leptin levels and body mass index (F=5.8, P <0.00001). Conclusions We show an independent association between leptin levels and heart rate in heart transplant recipients. We speculate that this may be due, in part, to a direct effect of leptin on heart rate, conceivably mediated through cardiac leptin receptors.
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement
Lee, Agnes , Agnelli, Giancarlo, Büller, Harry, Ginsberg, Jeffrey S., Heit, John A. , Rote, William E., Vlasuk, George P., Costantini, Lorrie, Julian, Jim A. , Comp, Philip C. , Meer, Jan van der, Piovella, Franco, Raskob, Gary E., Gent, Michael

Mayo Clinic

Circulation | September 28, 2007 | Volume: 104 | Issue: 1 | Pages: 74-78

10.1161/hc2601.091386 | PMID 11435341 Get It

Background —With the best prophylactics now available, venous thromboembolism after total knee replacement remains substantial (25% to 27%). Recombinant nematode anticoagulant protein c2 (rNAPc2) is a potent inhibitor of factor VIIa/tissue factor complex that has the potential to reduce this risk. The present study was performed to determine an efficacious and safe dose of rNAPc2 for prevention of venous thromboembolism after elective, unilateral total knee replacement. Methods and Results —This open-label, sequential dose-ranging study was conducted in 11 centers in Canada, Europe, and the United States. Five regimens were tested. Injections were administered subcutaneously on the day of surgery (day 1) and days 3, 5, and optionally, day 7. Primary efficacy outcome was a composite of overall deep vein thrombosis based on mandatory unilateral venography (day 7±2) and confirmed symptomatic venous thromboembolism recorded ≤48 hours after the last dose of rNAPc2. Primary safety outcome was major bleeding ≤72 hours after the last dose. An independent, blinded Central Adjudication Committee assessed all outcome events. Of 293 patients studied, 251 (86%) could be evaluated for primary efficacy analysis. A dosage of 3.0 μg/kg administered within 1 hour after surgery provided the best observed results, with an overall deep vein thrombosis rate of 12.2%, a proximal deep vein thrombosis rate of 1.3%, and a major bleeding rate of 2.3%. Conclusions —A randomized, double-blind trial that compared rNAPc2 with current best prophylactics is warranted based on encouraging, first-reported clinical results for a factor VIIa/tissue factor inhibitor evaluated for thrombosis prophylaxis.
A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study
Cooney-Qualter, Erin, Krailo, Mark , Angiolillo, Anne , Fawwaz, Rashid A., Wiseman, Gregory A., Harrison, Lauren , Kohl, Virginia, Adamson, Peter C. , Ayello, Janet, Ven, Carmella vande, Perkins, Sherrie L., Cairo, Mitchell S. , Ven, Carmella van de

Mayo Clinic

Clinical Cancer Research | September 17, 2007 | Volume: 13 | Issue: 18 | Pages: 5652s-5660s

10.1158/1078-0432.ccr-07-1060 | PMID 17875803 Get It

Abstract Purpose: The prognosis for children with recurrent CD20+ non–Hodgkin's lymphoma is dismal. A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell–non–Hodgkin's lymphoma. There is no data on the safety and feasibility of 90Y-IT in refractory childhood CD20+ lymphoma. Experimental Design: Children and adolescents with refractory/relapsed CD20+ lymphoma were eligible for this phase I radioimmunotherapy study. Patients (n = 5) received rituximab (250 mg/m2 i.v.) on days 0 and 7 and indium-111 ibritumomab-tiuxetan (5 mCi i.v.) on day 0. Dosimetry studies were done on days 0, 1, 3, and 6. Immediately after rituximab on day 7, patients received 90Y-IT if dosimetry studies showed &lt;2000 cGy exposure to all solid organs and &lt;300 cGy to marrow, as well as 0.4 mCi/kg in patients with good marrow reserve (n = 3) and 0.1 mCi/kg in patients with poor marrow reserve (after bone marrow transplant; n = 2). Results: No patients experienced nonhematologic or hematologic dose-limiting toxicity. Human antimurine antibody/human antichimeric antibody incidence was 0%. One patient experienced grade II infusion–related chills associated with rituximab. The following are the means of organ radiation exposure (cGy): kidneys 341 (112-515), liver 345 (83-798), lungs 309 (155-519), marrow 46 (20-78), spleen 565 (161-816), and total body 42 (14-68). Conclusions: Based on these findings, an expanded investigator-initiated limited institutional phase II study has been designed to further evaluate the safety, tolerability, and response rate with 90Y-IT dose stratification based on marrow reserve.
The clinical challenge of recognizing infratentorial empyema
Beek, Diederik van de , Campeau, Norbert G. , Wijdicks, Eelco F. M.

Mayo Clinic

Neurology | July 30, 2007 | Volume: 69 | Issue: 5 | Pages: 477-481

10.1212/01.wnl.0000266631.19745.32 | PMID 17664407 Get It

Contribution of In Vivo Structural Measurements and Load/Strength Ratios to the Determination of Forearm Fracture Risk in Postmenopausal Women
Melton, L. Joseph, Riggs, B. Lawrence, Lenthe, Harry van , Achenbach, Sara J., Müller, Ralph , Bouxsein, Mary , Amin, Shreyasee , Atkinson, Elizabeth J. , Khosla, Sundeep , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | May 31, 2007 | Volume: 22 | Issue: 9 | Pages: 1442-1448

10.1359/jbmr.070514 | PMID 17539738 Get It

Abstract Bone structure, strength, and load-strength ratios contribute to forearm fracture risk independently of areal BMD. Introduction: Technological and conceptual advances provide new opportunities for evaluating the contributions of bone density, structure, and strength to the pathogenesis of distal forearm fractures. Materials and Methods: From an age-stratified random sample of Rochester, MN, women, we compared 18 with a distal forearm fracture (cases) to 18 age-matched women with no osteoporotic fracture (controls). High-resolution pQCT was used to assess volumetric BMD (vBMD), geometry, and microstructure at the ultradistal radius, the site of Colles' fractures. Failure loads in the radius were estimated from microfinite element (μFE) models derived from pQCT. Differences between case and control women were assessed, and the risk of fracture associated with each variable was estimated by logistic regression analysis. Results: Given similar heights, estimated loading in a fall on the outstretched arm was the same in cases and controls. However, women with forearm fractures had inferior vBMD, geometry, microstructure, and estimated bone strength. Relative risks for the strongest determinant of fracture in each of the five main variable categories were as follows: BMD (total vBMD: OR per SD change, 4.2; 95% CI, 1.4–12), geometry (cortical thickness: OR, 4.0; 95% CI, 1.4–11), microstructure (trabecular number: OR, 2.3; 95% CI, 1.02–5.1), and strength (axial rigidity: OR, 3.8; 95% CI, 1.4–10); the factor-of-risk (fall load/μFE failure load) was 24% greater (worse) in cases (OR, 3.0; 95% CI, 1.2–7.5). Areas under ROC curves ranged from 0.72 to 0.82 for these parameters. Conclusions: Bone geometry, microstructure, and strength contribute to forearm fractures, as does BMD, and these additional determinants of risk promise greater insights into fracture pathogenesis.